MicroIslet strengthens islet cell transplant position:
This article was originally published in Clinica
MicroIslet says that its protective intellectual property portfolio in the field of islet cell transplantation has received a boost. The statement comes after its processes for culturing and transplanting functional and viable islet cells - the major insulin-secreting cells - into people with insulin-dependent (type 1) diabetes mellitus was awarded a US patent. The patent is licensed exclusively to the San Diego, California company under an agreement with Duke University in Durham, North Carolina.
You may also be interested in...
The US Food and Drug Administration posted two device-related closeout letters in November.
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.